LOS ANGELES, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 25, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Syneos Health, Inc. ("Syneos" or the "Company") (NASDAQ:SYNH) common stock between September 9, 2020 and November 3, 2022, inclusive (the "Class Period").
If you suffered a loss on your Syneos investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Syneos-Health-Inc-1/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
On February 17, 2022, Syneos disclosed that its reimbursable expenses would likely never recover to pre-pandemic levels and that $3.8 billion of the Company's Clinical Solutions backlog was at risk of never being collected. On this news, Syneos's stock price fell $4.01, or 4.8%, to close at $79.36 on February 17, 2022, thereby injuring investors.
Then, on August 2, 2022, Syneos revealed that net new business awards within the Clinical Solutions segment had declined by approximately 34%. Additionally, the Company reduced its expected revenue for 2022 by $185 million. On this news, Syneos's stock price fell $13.94, or 17.6%, to close at $65.20 on August 2, 2022.
Then, on September 13, 2022, Syneos disclosed that it expected to announce a book-to-bill ratio in its Clinical Solutions segment in the range of 1.05x ...
SYNH)>Full story available on Benzinga.com